Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIα genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization

被引:0
|
作者
Murthy, SK
Magliocco, AM
Demetrick, DJ
机构
[1] Univ Calgary, Calgary Lab Serv, Dept Pathol, Calgary, AB T2N 1N4, Canada
[2] Univ Calgary, Calgary Lab Serv, Dept Oncol, Calgary, AB T2N 1N4, Canada
[3] Univ Calgary, Calgary Lab Serv, Dept Med Biochem, Calgary, AB T2N 1N4, Canada
[4] Tom Baker Canc Clin, Calgary, AB, Canada
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-The Topoisomerase IIalpha (TOP2A) protein is the target of the anthracycline class of chemotherapeutic agents. TOP2A is frequently coamplified with c-erb-B2 and consequently might be a prognostic and/or predictive factor for breast cancer patients when anthracycline-based chemotherapy is a consideration. A total of 20% to 35% of breast carcinomas show amplification of the erb-B2 gene, some of which also have coamplification of the TOP2A gene. Investigation of the prognostic or predictive significance of these gene amplifications requires a reliable and sensitive method for the measurement of gene copy number in clinical tumor samples. Objective.-To assess 2 different assay methods that might allow accurate, reproducible, quantitative, and high-throughput estimation of gene copy number in fresh, frozen, or paraffin-em bedded breast cancer specimens. Design.-We developed an assay and analyzed the gene copy numbers of the erb-B2 and TOP2A genes in 8 breast cancer cell lines, 6 fresh frozen samples, and 38 paraffin-embedded breast tumor specimens by a novel real-time polymerase chain reaction (PCR) assay using hybridization probes. The results were compared with standard fluorescence in situ hybridization. Results.-We discovered a 100% concordance between assessment of gene copy number of erb-B2 and TOP2A between quantitative PCR and fluorescence in situ hybridization (FISH). Quantitative PCR also had the additional feature of uncovering an erb-B2 gene polymorphism. Finally, we observed that TOP2A amplification only occurred in conjunction with erb-B2 amplification in our paraffin-embedded cases of invasive breast carcinoma and that this event was present in 5 (42%) of 12 erb-B2 amplified cases. Conclusions.-We conclude that the potentially automatic, real-time PCR analysis using hybridization probes is an efficient method to perform copy number analysis, with results that appear identical to the FISH technique and with the benefit of identifying HER-2 polymorphisms.
引用
收藏
页码:39 / 46
页数:8
相关论文
共 44 条
  • [1] Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction
    Kim, Min A.
    Jung, Eun Ji
    Lee, Hye Seung
    Lee, Hee Eun
    Jeon, Yoon Kyung
    Yang, Han-Kwang
    Kim, Woo Ho
    HUMAN PATHOLOGY, 2007, 38 (09) : 1386 - 1393
  • [2] HER-2/neu gene copy quantified by real-time PCR and serum HER-2/neu by Elisa assay: comparison with fluorescence in situ hybridization and immunohistochemistry
    Tse, C.
    Brault, D.
    Gligorov, J.
    Antoine, M.
    Lelay, K.
    Lotz, J. P.
    EJC SUPPLEMENTS, 2004, 2 (03): : 171 - 171
  • [3] HER-2/neu overexpression and amplification in uterine serous papillary carcinoma:: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization
    Odicino, F. E.
    Bignotti, E.
    Rossi, E.
    Pasinetti, B.
    Tassi, R. A.
    Donzelli, C.
    Falchetti, M.
    Fontana, P.
    Grigolato, P. G.
    Pecorelli, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (01) : 14 - 21
  • [4] Her2/neu amplification in breast carcinoma: Comparison of real-time quantitative polymerase chain reaction (PCR), immunohistochemistry (IHC) and flourescent in situ hybridization (FISH)
    Smolkin, MB
    Mahadevia, P
    Vuolo, M
    Ramesh, KH
    Cannizzaro, L
    Ratech, H
    Schultz, C
    LABORATORY INVESTIGATION, 2003, 83 (01) : 48A - 48A
  • [5] Her2/neu amplification in breast carcinoma: Comparison of real-time quantitative polymerase chain reaction (PCR), immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH)
    Smolkin, MB
    Mahadevia, P
    Vuolo, M
    Ramesh, KH
    Cannizzaro, L
    Ratech, H
    Schultz, C
    MODERN PATHOLOGY, 2003, 16 (01) : 48A - 48A
  • [6] Comparison of immunohistochemical and fluorescence in situ hybridization assessment for topoisomerase IIalpha gene and HER-2/NEU status in breast carcinoma
    Neagu, M.
    Andrei, F.
    Butur, G.
    Diana, T.
    Georgescu, A.
    Ardeleanu, C.
    FEBS JOURNAL, 2008, 275 : 340 - 340
  • [7] Comparison of fluorescence in situ hybridization and immunohistochemical analysis for HER-2/neu detection in breast carcinoma.
    Li, Y
    Battaglia, T
    Davis, M
    Hankins, L
    Hagemeister, S
    Arthur, T
    Tawfik, O
    Persons, D
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 118 (04) : 641 - 642
  • [8] Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
    Persons, DL
    Borelli, KA
    Hsu, PH
    MODERN PATHOLOGY, 1997, 10 (07) : 720 - 727
  • [9] Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis
    Lehr, HA
    Jacobs, TW
    Yaziji, H
    Schnitt, SJ
    Gown, AM
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2001, 115 (06) : 814 - 822
  • [10] Comparative evaluation of the HER-2 gene status in breast carcinoma with immunohistochemistry, chromogenic in situ hybridization and real-time quantitative PCR
    Rousseau, A.
    Murie, B.
    Martinet, N.
    Ventard, E.
    Weinbreck, N.
    Bressenot, A.
    Montagne, K.
    Leroux, A.
    Vignaud, J. M.
    LABORATORY INVESTIGATION, 2008, 88 : 52A - 52A